Ajanta Pharma Limited (AJANTPHARM.BO)
INR 2491.9
(4.95%)
INR 2491.9
(4.95%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 21.06 Billion INR | -21.76% |
| 2022 | 26.92 Billion INR | 12.3% |
| 2021 | 23.97 Billion INR | 10.75% |
| 2020 | 21.64 Billion INR | 15.66% |
| 2019 | 18.71 Billion INR | 17.49% |
| 2018 | 15.92 Billion INR | 0.32% |
| 2017 | 15.87 Billion INR | 9.82% |
| 2016 | 14.45 Billion INR | 14.98% |
| 2015 | 12.57 Billion INR | 17.68% |
| 2014 | 10.68 Billion INR | 30.13% |
| 2013 | 8.21 Billion INR | 34.62% |
| 2012 | 6.09 Billion INR | 36.32% |
| 2011 | 4.47 Billion INR | 34.79% |
| 2010 | 3.31 Billion INR | 26.62% |
| 2009 | 2.62 Billion INR | 17.94% |
| 2008 | 2.22 Billion INR | 31.38% |
| 2007 | 1.69 Billion INR | 43.44% |
| 2006 | 1.17 Billion INR | 9.47% |
| 2005 | 1.07 Billion INR | 13.27% |
| 2004 | 951.32 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 9.24 Billion INR | 65.37% |
| 2024 Q1 | 5.59 Billion INR | 7.16% |
| 2023 Q4 | 5.21 Billion INR | -35.64% |
| 2023 Q1 | 7.69 Billion INR | 20.0% |
| 2023 Q2 | 7.72 Billion INR | 0.41% |
| 2023 FY | 21.06 Billion INR | -21.76% |
| 2023 Q3 | 8.1 Billion INR | 5.01% |
| 2022 Q4 | 6.4 Billion INR | -8.76% |
| 2022 FY | 26.92 Billion INR | 12.3% |
| 2022 Q2 | 6.78 Billion INR | 1.17% |
| 2022 Q3 | 7.02 Billion INR | 3.55% |
| 2022 Q1 | 6.7 Billion INR | 29.03% |
| 2021 FY | 23.97 Billion INR | 10.75% |
| 2021 Q4 | 5.19 Billion INR | -19.91% |
| 2021 Q1 | 5.76 Billion INR | 13.25% |
| 2021 Q3 | 6.48 Billion INR | -0.57% |
| 2021 Q2 | 6.52 Billion INR | 13.23% |
| 2020 Q3 | 5.8 Billion INR | 3.48% |
| 2020 Q4 | 5.08 Billion INR | -12.26% |
| 2020 FY | 21.64 Billion INR | 15.66% |
| 2020 Q1 | 5.15 Billion INR | 16.07% |
| 2020 Q2 | 5.6 Billion INR | 8.82% |
| 2019 Q3 | 4.82 Billion INR | 1.2% |
| 2019 Q2 | 4.76 Billion INR | 1.49% |
| 2019 Q1 | 4.69 Billion INR | 41.95% |
| 2019 FY | 18.71 Billion INR | 17.49% |
| 2019 Q4 | 4.43 Billion INR | -7.95% |
| 2018 FY | 15.92 Billion INR | 0.32% |
| 2018 Q4 | 3.3 Billion INR | -14.6% |
| 2018 Q3 | 3.87 Billion INR | -13.6% |
| 2018 Q2 | 4.48 Billion INR | 4.99% |
| 2018 Q1 | 4.26 Billion INR | -2.22% |
| 2017 Q2 | 4.31 Billion INR | 13.67% |
| 2017 Q1 | 3.79 Billion INR | -1.32% |
| 2017 FY | 15.87 Billion INR | 9.82% |
| 2017 Q4 | 4.36 Billion INR | -8.49% |
| 2017 Q3 | 4.77 Billion INR | 10.6% |
| 2016 Q3 | 4.26 Billion INR | 6.87% |
| 2016 Q2 | 3.99 Billion INR | 7.43% |
| 2016 Q1 | 3.71 Billion INR | 10.9% |
| 2016 FY | 14.45 Billion INR | 14.98% |
| 2016 Q4 | 3.84 Billion INR | -9.88% |
| 2015 Q4 | 3.35 Billion INR | -6.21% |
| 2015 FY | 12.57 Billion INR | 17.68% |
| 2015 Q2 | 3.38 Billion INR | 17.42% |
| 2015 Q3 | 3.57 Billion INR | 5.67% |
| 2015 Q1 | 2.87 Billion INR | 18.57% |
| 2014 Q1 | 2.42 Billion INR | 0.0% |
| 2014 Q4 | 2.42 Billion INR | -20.76% |
| 2014 FY | 10.68 Billion INR | 30.13% |
| 2014 Q3 | 3.06 Billion INR | 10.62% |
| 2014 Q2 | 2.77 Billion INR | 14.35% |
| 2013 FY | 8.21 Billion INR | 34.62% |
| 2012 Q1 | - INR | 0.0% |
| 2012 FY | 6.09 Billion INR | 36.32% |
| 2012 Q2 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2011 FY | 4.47 Billion INR | 34.79% |
| 2010 FY | 3.31 Billion INR | 26.62% |
| 2009 FY | 2.62 Billion INR | 17.94% |
| 2008 FY | 2.22 Billion INR | 31.38% |
| 2007 FY | 1.69 Billion INR | 43.44% |
| 2006 FY | 1.17 Billion INR | 9.47% |
| 2005 FY | 1.07 Billion INR | 13.27% |
| 2004 FY | 951.32 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 21.346% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 86.382% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | -69.42% |
| Granules India Limited | 16.79 Billion INR | -25.386% |
| Indoco Remedies Limited | 6.04 Billion INR | -248.665% |
| Achyut Healthcare Limited | 4.86 Million INR | -433226.476% |
| Alkem Laboratories Limited | 52.29 Billion INR | 59.722% |
| Alpa Laboratories Limited | 188.89 Million INR | -11051.169% |
| Brooks Laboratories Limited | 65.62 Million INR | -31999.97% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -238.503% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -1331.167% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -470.001% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 87.125% |
| Eris Lifesciences Limited | 10.42 Billion INR | -102.018% |
| FDC Limited | 8.33 Billion INR | -152.725% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 69.622% |
| Gufic Biosciences Limited | 4.16 Billion INR | -405.41% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -240.051% |
| Ipca Laboratories Limited | 29.8 Billion INR | 29.339% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -3127.754% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -10829.449% |
| Lasa Supergenerics Limited | 121.02 Million INR | -17303.95% |
| Laurus Labs Limited | 24.62 Billion INR | 14.444% |
| Lupin Limited | 123.71 Billion INR | 82.974% |
| Mankind Pharma Limited | 44.52 Billion INR | 52.687% |
| Medicamen Biotech Limited | 495.49 Million INR | -4151.102% |
| Medico Remedies Limited | 262.14 Million INR | -7935.278% |
| Megasoft Limited | 342.07 Million INR | -6057.786% |
| NATCO Pharma Limited | 25.73 Billion INR | 18.154% |
| Piramal Pharma Limited | 24.47 Billion INR | 13.922% |
| RPG Life Sciences Limited | 2.48 Billion INR | -748.329% |
| Sigachi Industries Limited | 2 Billion INR | -951.999% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 91.851% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -410.856% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -2135.147% |
| Unichem Laboratories Limited | 4.86 Billion INR | -332.976% |
| Wanbury Limited | 1.73 Billion INR | -1117.12% |
| Windlas Biotech Limited | 1.33 Billion INR | -1473.349% |
| ZIM Laboratories Limited | 1.26 Billion INR | -1562.658% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 83.177% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 3596.645% |
| Divi's Laboratories Limited | 32.44 Billion INR | 35.068% |
| Hester Biosciences Limited | 1.27 Billion INR | -1553.83% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -264.341% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -1253.265% |
| Bal Pharma Limited | 770.19 Million INR | -2634.892% |
| Strides Pharma Science Limited | 14.38 Billion INR | -46.399% |
| Venus Remedies Limited | 2.18 Billion INR | -865.094% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -261.22% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -608.734% |
| Shilpa Medicare Limited | 3.54 Billion INR | -493.877% |
| Aarti Drugs Limited | 8.31 Billion INR | -153.289% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -359.832% |
| Suven Life Sciences Limited | -200.79 Million INR | 10590.197% |
| Ind-Swift Limited | 2.17 Billion INR | -869.56% |
| Valiant Laboratories Limited | -60.66 Million INR | 34822.405% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 7.207% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -2345.889% |
| Themis Medicare Limited | 1.5 Billion INR | -1300.621% |
| Hikal Limited | 3.14 Billion INR | -570.171% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 54.95% |
| Sequent Scientific Limited | 2.97 Billion INR | -607.147% |
| Novartis India Limited | 1.32 Billion INR | -1487.459% |
| Wockhardt Limited | 16.24 Billion INR | -29.704% |
| Jubilant Pharmova Limited | 19.64 Billion INR | -7.234% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -144374.852% |
| Neuland Laboratories Limited | 8.24 Billion INR | -155.388% |
| Morepen Laboratories Limited | 6.16 Billion INR | -241.877% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -3294.808% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -2893.725% |